BofA warns Fed risks policy mistake with early rate cuts
Anish Patel, the Chief Operating Officer of Enliven Therapeutics Inc. (NASDAQ:ELVN), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On April 7, 2025, Patel sold a total of 6,667 shares of common stock in three separate transactions. The sales were executed at prices ranging from $17.8087 to $19.2721 per share, amounting to a total sale value of $120,268. The timing of the sale coincides with a challenging period for the stock, which has declined over 20% in the past week, according to InvestingPro data.
Following these transactions, Patel holds 316,643 shares indirectly through The Patel / Dong Family Trust. The sales were conducted as part of a pre-arranged trading plan under Rule 10b5-1, adopted in September 2024. Despite recent price weakness, analysts maintain a bullish outlook on ELVN, with price targets ranging from $33 to $42 per share, suggesting significant potential upside from current levels. InvestingPro subscribers can access additional insights, including 8 more key tips about the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.